Sorrento Announces the Full Enrollment of the Pivotal Phase

Sorrento Announces the Full Enrollment of the Pivotal Phase 3 Trial with Olgotrelvir (OVYDSOTM) (STI-1558), a Second Generation Oral Mpro Inhibitor, as a Standalone Treatment for COVID-19

Sorrento Announces the Full Enrollment of the Pivotal Phase 3 Trial with Olgotrelvir (OVYDSOTM) (STI-1558), a Second Generation Oral Mpro Inhibitor, as a Standalone Treatment for COVID-19

itbusinessnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from itbusinessnet.com Daily Mail and Mail on Sunday newspapers.

Related Keywords

China , United States , Shenzhen , Guangdong , American , Ronmeng Jiang , Brian Cooley , Henry Ji , Hongzhou Lu , China Health Authority National Medical Products Administration , Bankruptcy Court , Bankruptcy Court The Chapter , American Society For Microbiology , Scilex Pharmaceuticals Inc , Sorrento Therapeutics Inc , Exchange Commission , Semnur Pharmaceuticals Inc , Pivotal Trialc Le Ar Program , China Health Authority , National Medical Products Administration , Sorrento Therapeutics , Adult Subjects With Mild , American Society , Shenzhen Third Hospital , Deputy Dean , Beijing Ditan , Private Securities Litigation Reform Act , Annual Report , Quarterly Reports , Semnur Pharmaceuticals , Scilex Pharmaceuticals , All Rights ,